chang price
ahead investor summit nyc next tuesday thought would
good idea hammer lh thesi
lh transform global life scienc leader yield multipl
expans medium long term number key event
pama contract reset like open appeal entri
point share ultim consid threat concern
healthcar servic see lh lab cro right side
valu base care consumer possibl particip futur
vertic consolid dont expect investor summit
market move event inform session
encourag take look slide deck key question
think investor like contempl
key piec put togeth thesi
 undoubtedli headwind pama could also prove
catalyst condens increment share
expens higher cost ineffici competitor
 pama cut could bless disguis lh take share
 see much increment share potenti
next year could add overal lab
revenu growth info slide
 event big data becom key differenti cro
space forese lh suprem posit anticip
gain share outgrow market overal increasingli
evid book
 share may react neg open
contract would buyer overreact
headwind like manag similar decis
anoth could also help off-set hit
 margin base lab near matur see
omx upsid cro yield oi
 addit see lh converg toward cro tool peer
time growth acceler return improv broadli
continu next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
expect investor summit
thought lh transform lead clinic lab global leader life scienc
integr lab data clinic research come exampl big data yield enhanc market share
impact trial recruit execut
updat pama headwind acla lawsuit progress
launchpad progress base busi updat recent chang cro progress
well path laid om go medium long term
manag think lh fit within increasingli vertic integr also consum centric potenti valu
conclus all-in anticip increment disclosur would caus materi volatil share next week
messag clearli construct inform compani journey clinic lab leader diversifi global life
scienc compani past year well underway expect central messag eman
present time would also expect lh take share network lab potenti result
scenario yield growth acceler next decad reiter outperform rate rais pt impli
upsid current level
last page report import disclosur regard stock report
lh journey becom global life scienc compani well underway posit return
head lh investor summit decid take look key question investor like
contempl like inform market move event view
labcorp journey clinic lab leader diversifi global life scienc compani past
year expect central messag eman present
furthermor expect updat integr lab data clinic research come
exampl big data yield enhanc market share impact trial recruit execut
lab event would complet without updat pama although expect noth ground break
rel headwind acla lawsuit progress
turn margin anticip increment color success launchpad base lab
busi updat recent chang cro progress well path laid
om go medium long term
lastli expect manag address lh fit within increasingli vertic integr also
consum centric potenti valu base care world
all-in view updat clearli construct anticip increment disclosur would
caus materi volatil share
lh journey take en rout true global life sci compani
world shift big data lab cro lh posit
much room left expand oper margin
go see clinic lab gain share post pama
lh fit consumer-centr valu base care world
metamorphosi diversifi life scienc provid underway
first danc given covanc
revenu mix increasingli favor balanc
novemb lh acquir covanc cvd
bn take control one biggest cro
time longer stand lead clinic lab
initi investor feedback mix time mani
began warm idea manag ahead
curv util big data enhanc clinic trial
manag went hit key synergi target howev
recent investor still question execut
cvd revenu mix due industry-wid
disrupt also hamper omx
recent guidanc solidifi view manag
program improv cvd take hold market
forc blame prior volatil
see cvd post chiltern prime revenu
broad presenc life sci alreadi rapidli deepen
key tuck-in life scienc lh
transform journey broadli compet tool
addit sequenom sqnm
develop relationship steadili
strengthen compani presenc advanc dx
cro bn cash help bulk lh
presenc small-to-medium size biopharma
compani faster growth vs cro client group
cvd underweight segment base clinic
addit chiltern also provid signific
present asia addit establish earli phase
oncolog medic devic expertis
partnership anoth need area expans cvd
area increas interest
see chiltern plug solv cvd
cro multipl tend trade line slight premium market
cro ev/ebitda trade averag premium vs last year
p/e trade averag premium vs last year
tool dx trade consist elev level rel market
tool dx ev/ebitda trade averag premium vs last year
tool dx price-to-earnings trade averag premium vs last year
lab multipl histor trade discount
lab lh ev/ebitda trade averag discount vs last year
lab lh p/e trade averag discount vs last year
impli given favor mix shift lh see multipl expans time
labcorp ahead curv big data push
data set
compani well-
posit
physician
interfac
phd
compani alreadi see benefit via
market begin increasingli differenti uniqu data capabl labcorp
well-posit gain share
dx margin matur signific opportun exist cro
launchpad success expect upsiz focu shift dx cvd
headcount rightsiz implement gener mm increment save
key lever autom global share servic tools/technolog procur aid chiltern capabl expertis
cost initi continu expans constant improvement/combat pama price headwind
labcorp oper margin room expand time mostli cro see omx opportun
pama cut could bless disguis lh take share
impact pama felt
pama cut potenti bless disguis
price clinic lab test issu pama
gone well lab shave
lh challeng object
process use determin rate without
doubt issu continu put pressur lab
fundament final rule determin
struggl logic use end
ultim price approach cut
stay model adjust realiti multi-
said see hit manag particularli
given numer posit factor busi
also given likelihood acceler manag
result pama price cut player outsid
like struggl increas awar
payer could incentiv shift lower cost provid
largest lab choos monet outreach asset
lh help mix share gain
view system benefit lab gain much
need increment volum posit lh
think time lh could take littl
quarter indpt lab market gain increment share
refer test combin opportun
bn next year
addit net impact partial loss
contract partial gain anoth contract
provid anoth lever compani take share
similar sub-seg hc lh/dgx becom profound player oligopolist indpt lab market
lh could take increment share indpt ref test market
indpt lab segment rep total market
lh could take addit share indpt market
 lh
share
total market outsid hospit vs inpt
lh could take refer test market
indpt lab
hospit
drop bp
bp
outsid hospit
ref test
outsid hospit
post-pama indpt market could oligopolist w/ lh leader
lh current hold indpt market
consum incentiv go lh/dgx
outsid
outsid
rev lh go increment bn time take addit market
repres upsid top-line estim bn assum year transit
renewal/re-pr overhang could present opportun
lh contract overhang gener manag
see open anoth like follow
lh current contract nation laboratori
estim repres mm
revenu lh evr
contract renew end
anoth contract also renew
medium term
view anoth shift
multisourc lh
open contract run contrast mani
arrang see healthcar servic
narrow network drive save payer
provid trade price volum
contend commerci busi
cut somewher anoth
contract open share lh
manag headwind time
said likeliest rang price haircut upon
renew re-structur multisourc contract
would rang possibl take
somewher share anoth
contract off-set much headwind
share gain could ultim end posit
contract headwind off-set anoth contract req increas share time off-set
share net imapct share requir share headwind februari
overal lh also well-posit consumer vbc
servic center
retail
enhanc drug
care deliveri
influenc
hc decision-
reduc
overal cost
metamorphosi well underway remain construct buyer relat weak
contend lh transform global life scienc leader yield multipl expans
medium long term
event big data becom key differenti cro space forese lh suprem posit
anticip gain share outgrow market overal increasingli evid book
margin base lab near matur see omx upsid cro
pama undoubtedli headwind could also prove catalyst condens increment share
expens higher cost ineffici competitor
see much increment share potenti next year could add overal
share may react neg open contract would buyer overreact
headwind like manag similar decis anoth could also help off-set hit
time would also expect lh take share network potenti result
scenario yield net accret within month
consid threat concern healthcar servic see lh lab cro right side
valu base care consumer possibl particip futur vertic consolid
reiter outperform rate rais pt impli upsid current level
pleas feel free reach question follow-up
medic suppli devic
laboratori corp america stat million except per share data fy end septemb volum organ gp growth revenu margin ep share net incom price-to-earnings premium/discount isi healthcar technolog distribut februari
valuat methodolog base mix discount cash flow analysi rel valuat multipl
downsid risk potenti pama relat price cut bleed commerci price ultim lead neg
margin cycl recent vertic integr hc servic organ lead increas price pressur given heighten focu
unit cost challeng associ integr small outreach lab deal could depress return invest capit prove
distract effort off-set pama cut increas cost save could yield servic challeng ultim depress core
organ volum poor perform major clinic trial could harm cvd reput lead signific shift cro
relat market share signific down-tick biotech relat fund could lead materi growth downshift earli phase
laboratori corp america hold
articl articl
time dissemin februari et
analyst ross muken elizabeth anderson suzi yoon primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view
